Hsbc Holdings PLC Takes Position in Medpace Holdings, Inc. $MEDP

Hsbc Holdings PLC acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 3,829 shares of the company’s stock, valued at approximately $2,164,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace during the fourth quarter worth about $30,000. Elyxium Wealth LLC purchased a new position in shares of Medpace in the fourth quarter valued at approximately $30,000. Quarry LP acquired a new position in shares of Medpace in the third quarter valued at approximately $35,000. Finally, Bayban purchased a new stake in Medpace during the 4th quarter worth approximately $44,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 0.5%

MEDP traded up $2.73 on Friday, reaching $538.23. The company’s stock had a trading volume of 177,537 shares, compared to its average volume of 312,394. The company has a market capitalization of $15.37 billion, a price-to-earnings ratio of 33.83, a P/E/G ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a fifty-two week low of $306.70 and a fifty-two week high of $628.92. The stock has a 50 day moving average of $467.24 and a two-hundred day moving average of $496.03.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. During the same quarter in the previous year, the firm earned $3.67 EPS. The company’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on MEDP. Robert W. Baird reissued a “neutral” rating and issued a $547.00 price target (up from $477.00) on shares of Medpace in a research report on Wednesday. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and lifted their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Royal Bank Of Canada reduced their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Barclays lowered their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. Finally, Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $469.17.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.